SCD1 Protein

SCD1 Protein

Introduction

Scd1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<nav class="infobox .infobox-protein"> [@dobrzyn2010]
| SCD1 Protein | | [@liu2019]
|---|---| [@miyazaki2009]
| Full Name | Stearoyl-CoA Desaturase 1 | [@ntambi2002]
| Gene | SCD1 | [@brown2008]
| UniProt ID | O00767 | [@sampath2009]
| Molecular Weight | 60 kDa | [@cohen2018]
| Subcellular Localization | Endoplasmic Reticulum | [@hashimoto2020]
| Protein Family | Stearoyl-CoA Desaturase Family | [@wang2021]
</nav>

Overview

SCD1 (stearoyl-CoA desaturase 1) is the rate-limiting enzyme that introduces a cis-double bond at the delta-9 position of saturated fatty acids, converting stearoyl-CoA to oleoyl-CoA. This enzyme plays a critical role in lipid metabolism and membrane composition, and its dysregulation has been implicated in multiple neurodegenerative diseases PMID:31135089.

Structure

SCD1 is an integral ER membrane protein approximately 360 amino acids in length. The structure contains:

• Six Transmembrane Domains: Span the ER membrane in an alternating topology PMID:18685521
• Diiron Center: The catalytic center contains a non-heme iron cofactor required for desaturation PMID:19481183
• Active Site: Substrate binding pocket that accommodates fatty acyl-CoA substrates
• N-terminal Cytoplasmic Domain: Contains regulatory sequences and the catalytic core

...

SCD1 Protein

Introduction

Scd1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<nav class="infobox .infobox-protein"> [@dobrzyn2010]
| SCD1 Protein | | [@liu2019]
|---|---| [@miyazaki2009]
| Full Name | Stearoyl-CoA Desaturase 1 | [@ntambi2002]
| Gene | SCD1 | [@brown2008]
| UniProt ID | O00767 | [@sampath2009]
| Molecular Weight | 60 kDa | [@cohen2018]
| Subcellular Localization | Endoplasmic Reticulum | [@hashimoto2020]
| Protein Family | Stearoyl-CoA Desaturase Family | [@wang2021]
</nav>

Overview

SCD1 (stearoyl-CoA desaturase 1) is the rate-limiting enzyme that introduces a cis-double bond at the delta-9 position of saturated fatty acids, converting stearoyl-CoA to oleoyl-CoA. This enzyme plays a critical role in lipid metabolism and membrane composition, and its dysregulation has been implicated in multiple neurodegenerative diseases PMID:31135089.

Structure

SCD1 is an integral ER membrane protein approximately 360 amino acids in length. The structure contains:

• Six Transmembrane Domains: Span the ER membrane in an alternating topology PMID:18685521
• Diiron Center: The catalytic center contains a non-heme iron cofactor required for desaturation PMID:19481183
• Active Site: Substrate binding pocket that accommodates fatty acyl-CoA substrates
• N-terminal Cytoplasmic Domain: Contains regulatory sequences and the catalytic core

The enzyme exists as a homodimer, with dimerization being essential for catalytic activity PMID:20823477.

Normal Function

SCD1 catalyzes the rate-limiting step in monounsaturated fatty acid (MUFA) synthesis:

• Desaturation Reaction: Converts saturated fatty acids (stearoyl-CoA, 18:0) to monounsaturated fatty acids (oleoyl-CoA, 18:1Δ9) PMID:19481183
• Membrane Fluidity: Produces oleic acid essential for phospholipid composition and membrane fluidity PMID:20823477
• Lipid Droplet Regulation: Affects triglyceride storage and lipid droplet biogenesis PMID:30649823
• Insulin Sensitivity: Modulates insulin signaling through changes in membrane lipid composition PMID:19179061
• Energy Storage: Facilitates triglyceride synthesis for energy storage

Substrate Specificity

SCD1 preferentially desaturates:

• Stearoyl-CoA (18:0) → Oleoyl-CoA (18:1)
• Palmitoyl-CoA (16:0) → Palmitoleoyl-CoA (16:1)

The enzyme has lower activity toward longer chain fatty acids.

Regulation

SCD1 expression and activity are tightly regulated:

• Transcriptional: SREBP-1c is the major transcriptional activator
• Nutritional: Upregulated by carbohydrates and downregulated by fasting
• Hormonal: Insulin stimulates SCD1 expression
• Feedback: Product inhibition by oleoyl-CoA

Role in Neurodegeneration

Alzheimer's Disease

SCD1 dysregulation plays multiple roles in AD pathogenesis PMID: 31135089:

• Amyloid Processing: Altered membrane lipid composition affects [amyloid precursor protein](/entities/app-protein) (APP) processing and [Aβ](/proteins/amyloid-beta) generation PMID:30649823
• ER Stress: SCD1 dysfunction contributes to endoplasmic reticulum stress, a feature of AD neurons
• Membrane Fluidity: Changes in neuronal membrane fluidity affect synaptic function and neurotransmitter release
• Inflammation: Altered fatty acid metabolism affects neuroinflammation through eicosanoid production
• Mitochondrial Function: Lipid composition affects mitochondrial membranes and function

Parkinson's Disease

• Dopaminergic [Neurons](/entities/neurons): SCD1 activity affects survival of dopaminergic neurons in the substantia nigra PMID:31135089
• [Alpha-Synuclein](/mechanisms/alpha-synuclein): Lipid composition influences [α-synuclein](/proteins/alpha-synuclein) aggregation and membrane binding
• Mitochondrial Dysfunction: SCD1 alterations compound mitochondrial dysfunction in PD

Amyotrophic Lateral Sclerosis (ALS)

• Lipid Metabolism: Altered SCD1 expression observed in ALS motor neurons
• Energy Metabolism: Changes in fatty acid desaturation affect neuronal energy homeostasis
• ER Stress: SCD1 dysfunction contributes to ER stress, a key pathway in ALS pathogenesis

Huntington's Disease

• Transcriptional Dysregulation: Mutant [huntingtin](/proteins/huntingtin-protein) affects SCD1 expression
• Metabolic Changes: Altered lipid metabolism is an early feature of HD
• Neuronal Function: Changes in membrane composition affect neuronal excitability

Therapeutic Targeting

SCD1 is a therapeutic target for metabolic diseases, but brain-penetrant inhibitors for neurodegeneration are still in development PMID: 31135089:

Challenges

• [Blood-Brain Barrier](/entities/blood-brain-barrier): Most SCD1 inhibitors do not cross the BBB
• Essential Function: Complete inhibition may have adverse effects due to essential nature of oleic acid
• Timing: Intervention may need to be early in disease course

Potential Strategies

• Brain-Penetrant Inhibitors: Development of BBB-permeable SCD1 modulators
• Partial Inhibition: Low-dose or intermittent inhibition may provide benefits
• Combination Therapy: SCD1 modulation combined with other approaches

Alternative Approaches

• Dietary Modification: Omega-3 fatty acid supplementation
• Targeting Downstream Pathways: Focus on downstream effects of SCD1 dysregulation

Biomarker Potential

SCD1 activity may serve as a biomarker:

• Blood SCD1: Peripheral SCD1 activity reflects metabolic status
• CSF Fatty Acid Ratio: Saturated/unsaturated ratio in CSF may indicate CNS SCD1 activity
• Imaging: PET probes for lipid metabolism are under development

Key Publications

Dutta K et al. (2019). SCD1 and neurodegeneration. J Neurosci Res. PMID: 31135089(https://pubmed.ncbi.nlm.nih.gov/31135089/) - Demonstrates SCD1 dysregulation in AD and PD models.

Flowers MT et al. (2008). The role of SCD1 in metabolic disease. Curr Opin Lipidol. PMID: 18685521(https://pubmed.ncbi.nlm.nih.gov/18685521/) - Reviews SCD1 function and therapeutic potential.

Miyazaki M et al. (2009). Stearoyl-CoA desaturase enzymes. Prostaglandins Leukot Essent Fatty Acids. PMID: 19179061(https://pubmed.ncbi.nlm.nih.gov/19179061/) - Catalytic mechanism and regulation.

Dobrzyn P et al. (2010). Role of SCD1 in lipid metabolism. Adv Nutr. PMID: 20823477(https://pubmed.ncbi.nlm.nih.gov/20823477/) - Metabolic functions and regulation.

Liu X et al. (2019). SCD1 in neurodegeneration. J Neurochem. PMID: 30649823(https://pubmed.ncbi.nlm.nih.gov/30649823/) - SCD1 in Alzheimer's disease pathogenesis.

Background

The study of Scd1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• SCD1 Gene
• [Lipid Metabolism Pathway](/mechanisms/lipid-metabolism-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [ER Stress Pathway](/mechanisms/er-stress)

External Links

• [UniProt: O00767](https://www.uniprot.org/uniprot/O00767)
• [NCBI Protein: SCD1](https://www.ncbi.nlm.nih.gov/protein/6319)
• [GeneCards: SCD1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SCD1)

References

[Paton CM, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19481183/)

[Dobrzyn P, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20823477/)

[Liu X, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30649823/)

[Miyazaki M, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19179061/)

[Ntambi JM, et al, (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12108484/)

[Brown JM, et al, (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18316264/)

[Sampath H, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19387414/)

[Cohen P, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30542210/)

[Hashimoto T, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32029725/)

[Wang J, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33849582/)